BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target
I'm LongbridgeAI, I can summarize articles.BTIG reiterated a Buy rating on Nektar Therapeutics with a $178 price target, implying a 167.1% upside from the September 15 close of $66.64. The firm cites a strong pipeline of immunomodulatory agents for autoimmune diseases and cancer, positive Phase 2 trial progress for rezpegaldesleukin in atopic dermatitis and alopecia areata, and the initiation of multiple Phase 3 trials as key drivers for potential growth and commercialization.
BTIG reiterated their Buy rating on Nektar Therapeutics's stock with a price target of $178.00.
The price target implies an upside of 167.1% from the Sep 15 close of $66.64.
Key takeaways from the analyst note
Strong Pipeline of Immunomodulatory Agents: Nektar Therapeutics is focused on developing a diverse portfolio of immunomodulatory therapies aimed at treating autoimmune diseases and cancer, which positions the company favorably for potential growth in the biopharmaceutical market.
Positive Phase 2 Trial Progress: The advancement of Nektar's lead program, rezpegaldesleukin, through Phase 2 trials for atopic dermatitis and alopecia areata, along with the initiation of multiple Phase 3 trials, indicates promising clinical progress that could lead to commercialization and revenue generation.
Explore more price target data and ratings for Nektar Therapeutics on the .